NASDAQ:MBII

Marrone Bio Innovations Competitors

$1.83
-0.02 (-1.08 %)
(As of 04/22/2021 12:40 PM ET)
Add
Compare
Today's Range
$1.83
Now: $1.83
$1.88
50-Day Range
$1.71
MA: $2.11
$2.54
52-Week Range
$0.65
Now: $1.83
$2.90
Volume4,130 shs
Average Volume638,161 shs
Market Capitalization$317.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.22

Competitors

Marrone Bio Innovations (NASDAQ:MBII) Vs. NTR, SMG, MOS, CF, ICL, and AVD

Should you be buying MBII stock or one of its competitors? Companies in the industry of "agricultural chemicals" are considered alternatives and competitors to Marrone Bio Innovations, including Nutrien (NTR), The Scotts Miracle-Gro (SMG), The Mosaic (MOS), CF Industries (CF), ICL Group (ICL), and American Vanguard (AVD).

Marrone Bio Innovations (NASDAQ:MBII) and Nutrien (NYSE:NTR) are both basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Marrone Bio Innovations and Nutrien's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71
Nutrien$20.02 billion1.54$992 million$2.1724.95

Nutrien has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than Nutrien, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

34.5% of Marrone Bio Innovations shares are held by institutional investors. Comparatively, 61.9% of Nutrien shares are held by institutional investors. 4.7% of Marrone Bio Innovations shares are held by insiders. Comparatively, 3.1% of Nutrien shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Marrone Bio Innovations and Nutrien, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marrone Bio Innovations00303.00
Nutrien15612.54

Marrone Bio Innovations currently has a consensus price target of $3.6667, indicating a potential upside of 100.36%. Nutrien has a consensus price target of $56.4444, indicating a potential upside of 4.14%. Given Marrone Bio Innovations' stronger consensus rating and higher possible upside, research analysts plainly believe Marrone Bio Innovations is more favorable than Nutrien.

Risk & Volatility

Marrone Bio Innovations has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Nutrien has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Marrone Bio Innovations and Nutrien's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marrone Bio Innovations-69.75%-91.71%-29.59%
Nutrien0.47%4.19%1.98%

Summary

Nutrien beats Marrone Bio Innovations on 11 of the 15 factors compared between the two stocks.

Marrone Bio Innovations (NASDAQ:MBII) and The Scotts Miracle-Gro (NYSE:SMG) are both basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk and Volatility

Marrone Bio Innovations has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, The Scotts Miracle-Gro has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Marrone Bio Innovations and The Scotts Miracle-Gro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marrone Bio Innovations-69.75%-91.71%-29.59%
The Scotts Miracle-Gro9.38%52.60%11.09%

Earnings & Valuation

This table compares Marrone Bio Innovations and The Scotts Miracle-Gro's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71
The Scotts Miracle-Gro$4.13 billion3.11$387.40 million$7.2431.84

The Scotts Miracle-Gro has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than The Scotts Miracle-Gro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Marrone Bio Innovations and The Scotts Miracle-Gro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marrone Bio Innovations00303.00
The Scotts Miracle-Gro00313.25

Marrone Bio Innovations currently has a consensus price target of $3.6667, suggesting a potential upside of 100.36%. The Scotts Miracle-Gro has a consensus price target of $250.00, suggesting a potential upside of 9.00%. Given Marrone Bio Innovations' higher probable upside, equities analysts plainly believe Marrone Bio Innovations is more favorable than The Scotts Miracle-Gro.

Insider & Institutional Ownership

34.5% of Marrone Bio Innovations shares are owned by institutional investors. Comparatively, 63.1% of The Scotts Miracle-Gro shares are owned by institutional investors. 4.7% of Marrone Bio Innovations shares are owned by insiders. Comparatively, 27.2% of The Scotts Miracle-Gro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

The Scotts Miracle-Gro beats Marrone Bio Innovations on 12 of the 14 factors compared between the two stocks.

The Mosaic (NYSE:MOS) and Marrone Bio Innovations (NASDAQ:MBII) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares The Mosaic and Marrone Bio Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Mosaic-13.05%N/AN/A
Marrone Bio Innovations-69.75%-91.71%-29.59%

Analyst Ratings

This is a breakdown of current ratings and target prices for The Mosaic and Marrone Bio Innovations, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Mosaic181002.47
Marrone Bio Innovations00303.00

The Mosaic currently has a consensus price target of $27.9722, suggesting a potential downside of 16.38%. Marrone Bio Innovations has a consensus price target of $3.6667, suggesting a potential upside of 100.36%. Given Marrone Bio Innovations' stronger consensus rating and higher probable upside, analysts clearly believe Marrone Bio Innovations is more favorable than The Mosaic.

Institutional & Insider Ownership

69.8% of The Mosaic shares are owned by institutional investors. Comparatively, 34.5% of Marrone Bio Innovations shares are owned by institutional investors. 0.5% of The Mosaic shares are owned by company insiders. Comparatively, 4.7% of Marrone Bio Innovations shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

The Mosaic has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Marrone Bio Innovations has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Valuation & Earnings

This table compares The Mosaic and Marrone Bio Innovations' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Mosaic$8.91 billion1.43$-1,067,400,000.00$0.19177.05
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71

Marrone Bio Innovations has lower revenue, but higher earnings than The Mosaic. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than The Mosaic, indicating that it is currently the more affordable of the two stocks.

Summary

The Mosaic beats Marrone Bio Innovations on 8 of the 14 factors compared between the two stocks.

CF Industries (NYSE:CF) and Marrone Bio Innovations (NASDAQ:MBII) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CF Industries and Marrone Bio Innovations, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CF Industries17602.36
Marrone Bio Innovations00303.00

CF Industries currently has a consensus target price of $43.9167, indicating a potential downside of 8.26%. Marrone Bio Innovations has a consensus target price of $3.6667, indicating a potential upside of 100.36%. Given Marrone Bio Innovations' stronger consensus rating and higher probable upside, analysts plainly believe Marrone Bio Innovations is more favorable than CF Industries.

Institutional & Insider Ownership

91.0% of CF Industries shares are owned by institutional investors. Comparatively, 34.5% of Marrone Bio Innovations shares are owned by institutional investors. 2.0% of CF Industries shares are owned by insiders. Comparatively, 4.7% of Marrone Bio Innovations shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

CF Industries has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Marrone Bio Innovations has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Profitability

This table compares CF Industries and Marrone Bio Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CF Industries7.00%5.14%2.34%
Marrone Bio Innovations-69.75%-91.71%-29.59%

Valuation & Earnings

This table compares CF Industries and Marrone Bio Innovations' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CF Industries$4.59 billion2.25$493 million$1.9324.97
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71

CF Industries has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than CF Industries, indicating that it is currently the more affordable of the two stocks.

Summary

CF Industries beats Marrone Bio Innovations on 10 of the 14 factors compared between the two stocks.

Marrone Bio Innovations (NASDAQ:MBII) and ICL Group (NYSE:ICL) are both basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Profitability

This table compares Marrone Bio Innovations and ICL Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marrone Bio Innovations-69.75%-91.71%-29.59%
ICL Group-0.12%5.99%2.56%

Institutional and Insider Ownership

34.5% of Marrone Bio Innovations shares are held by institutional investors. Comparatively, 7.4% of ICL Group shares are held by institutional investors. 4.7% of Marrone Bio Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Marrone Bio Innovations has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, ICL Group has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Marrone Bio Innovations and ICL Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marrone Bio Innovations00303.00
ICL Group02002.00

Marrone Bio Innovations presently has a consensus target price of $3.6667, indicating a potential upside of 100.36%. ICL Group has a consensus target price of $5.75, indicating a potential downside of 9.87%. Given Marrone Bio Innovations' stronger consensus rating and higher possible upside, research analysts clearly believe Marrone Bio Innovations is more favorable than ICL Group.

Valuation and Earnings

This table compares Marrone Bio Innovations and ICL Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71
ICL Group$5.27 billion1.56$475 million$0.3717.32

ICL Group has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than ICL Group, indicating that it is currently the more affordable of the two stocks.

Summary

ICL Group beats Marrone Bio Innovations on 8 of the 14 factors compared between the two stocks.

Marrone Bio Innovations (NASDAQ:MBII) and American Vanguard (NYSE:AVD) are both small-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Marrone Bio Innovations and American Vanguard, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marrone Bio Innovations00303.00
American Vanguard0000N/A

Marrone Bio Innovations presently has a consensus price target of $3.6667, suggesting a potential upside of 100.36%. Given Marrone Bio Innovations' higher probable upside, equities research analysts clearly believe Marrone Bio Innovations is more favorable than American Vanguard.

Profitability

This table compares Marrone Bio Innovations and American Vanguard's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marrone Bio Innovations-69.75%-91.71%-29.59%
American Vanguard2.40%3.16%1.61%

Insider & Institutional Ownership

34.5% of Marrone Bio Innovations shares are owned by institutional investors. Comparatively, 76.5% of American Vanguard shares are owned by institutional investors. 4.7% of Marrone Bio Innovations shares are owned by company insiders. Comparatively, 5.3% of American Vanguard shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Marrone Bio Innovations has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, American Vanguard has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Valuation & Earnings

This table compares Marrone Bio Innovations and American Vanguard's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marrone Bio Innovations$29.37 million10.81$-37,170,000.00($0.21)-8.71
American Vanguard$468.19 million1.35$13.60 million$0.4644.33

American Vanguard has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than American Vanguard, indicating that it is currently the more affordable of the two stocks.

Summary

American Vanguard beats Marrone Bio Innovations on 10 of the 13 factors compared between the two stocks.


Marrone Bio Innovations Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nutrien logo
NTR
Nutrien
1.7$54.14-0.0%$30.86 billion$20.02 billion318.47Analyst Revision
News Coverage
The Scotts Miracle-Gro logo
SMG
The Scotts Miracle-Gro
1.7$230.52-0.3%$12.88 billion$4.13 billion33.85
The Mosaic logo
MOS
The Mosaic
1.7$33.64-0.8%$12.65 billion$8.91 billion-11.72Analyst Upgrade
Analyst Revision
News Coverage
CF Industries logo
CF
CF Industries
1.8$48.20-1.0%$10.23 billion$4.59 billion36.52Analyst Revision
News Coverage
ICL Group logo
ICL
ICL Group
1.6$6.41-0.5%$8.24 billion$5.27 billion17.32
American Vanguard logo
AVD
American Vanguard
0.9$20.39-0.5%$633.49 million$468.19 million55.11
CVR Partners logo
UAN
CVR Partners
0.4$46.57-3.8%$478.90 million$404.18 million-4.95
Calyxt logo
CLXT
Calyxt
1.3$5.47-0.7%$201.76 million$7.30 million-4.11
Evogene logo
EVGN
Evogene
1.3$4.35-3.4%$115.88 million$750,000.00-5.37
China Green Agriculture logo
CGA
China Green Agriculture
0.8$13.90-5.8%$83.19 million$249.24 million-0.52News Coverage
Gap Down
SenesTech logo
SNES
SenesTech
1.5$1.58-2.5%$7.85 million$140,000.00-0.21
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.